Effectiveness and Safety of Rituximab in Filipino Patients With Relapsing-Remitting Multiple Sclerosis: A Real-World Retrospective Cohort Study in a Resource-Limited Setting.

While the downward trend in mean EDSS scores did not reach statistical significance, this is a common observation in observational MS studies where inflammatory markers typically respond more rapidly to anti-CD20 therapy than clinical disability [ 9 , 11 - 13 ].

also in 111,027 other papers